Wells Fargo & Company Aldeyra Therapeutics, Inc. Transaction History

Wells Fargo & Company

$429 Billion
Q1 2025

A detailed history of Wells Fargo & Company transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 392,532 shares of ALDX stock, worth $922,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares

392,532

Previous 393,654 0.29%

Holding current value

$922,450

Previous $1.96 Million 14.92%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$4.7 - $6.98 $5,273 - $7,831	-1,122 Reduced 0.29%	392,532 $2.26 Million
Q4 2024 Feb 12, 2025	BUY	$4.21 - $5.9 $30,935 - $43,353	7,348 Added 1.9%	393,654 $1.96 Million
Q3 2024 Nov 13, 2024	SELL	$3.19 - $6.32 $28,681 - $56,823	-8,991 Reduced 2.27%	386,306 $2.08 Million
Q2 2024 Aug 13, 2024	BUY	$3.25 - $4.72 $25,977 - $37,726	7,993 Added 2.06%	395,297 $1.31 Million
Q1 2024 May 10, 2024	BUY	$2.77 - $4.22 $116,869 - $178,046	42,191 Added 12.23%	387,304 $1.27 Million
Q4 2023 Feb 09, 2024	BUY	$1.47 - $6.06 $2,706 - $11,156	1,841 Added 0.54%	345,113 $1.21 Million
Q3 2023 Nov 13, 2023	BUY	$6.11 - $8.16 $20,749 - $27,711	3,396 Added 1.0%	343,272 $2.29 Million
Q2 2023 Aug 15, 2023	BUY	$7.11 - $11.89 $483,714 - $808,912	68,033 Added 25.03%	339,876 $2.85 Million
Q1 2023 May 12, 2023	SELL	$5.77 - $9.93 $265,443 - $456,819	-46,004 Reduced 14.47%	271,843 $2.7 Million
Q4 2022 Feb 13, 2023	BUY	$5.08 - $7.09 $37,800 - $52,756	7,441 Added 2.4%	317,847 $2.21 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $79,613 - $162,160	-20,951 Reduced 6.32%	310,406 $1.66 Million
Q2 2022 Aug 12, 2022	BUY	$2.43 - $4.85 $1,992 - $3,976	820 Added 0.25%	331,357 $1.32 Million
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $305,165 - $485,447	93,897 Added 39.68%	330,537 $1.47 Million
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $79,873 - $219,766	-22,821 Reduced 8.8%	236,640 $947,000
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $941,946 - $1.34 Million	118,633 Added 84.24%	259,461 $2.28 Million
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $690,626 - $982,357	66,152 Added 88.59%	140,828 $1.6 Million
Q1 2021 May 13, 2021	BUY	$6.53 - $14.42 $440,272 - $972,239	67,423 Added 929.59%	74,676 $887,000
Q4 2020 Feb 09, 2021	BUY	$6.31 - $8.13 $44,270 - $57,040	7,016 Added 2960.34%	7,253 $50,000
Q3 2020 Nov 05, 2020	SELL	$4.0 - $7.53 $1,112 - $2,093	-278 Reduced 53.98%	237 $2,000
Q2 2020 Aug 13, 2020	SELL	$1.97 - $5.05 $31,984 - $81,991	-16,236 Reduced 96.93%	515 $2,000
Q1 2020 May 14, 2020	BUY	$1.62 - $6.4 $27,136 - $107,206	16,751 New	16,751 $41,000

Others Institutions Holding ALDX

# of Institutions

139

Shares Held

38.6M

Call Options Held

620K

Put Options Held

435K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $137M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Aldeyra Therapeutics, Inc. Transaction History